IRIS
TALAMONTI, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.043
EU - Europa 1.021
AS - Asia 359
SA - Sud America 9
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 4
AF - Africa 1
Totale 14.445
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.032
IE - Irlanda 305
CN - Cina 225
IT - Italia 176
UA - Ucraina 115
DE - Germania 111
SE - Svezia 89
GB - Regno Unito 67
FR - Francia 62
KR - Corea 46
FI - Finlandia 22
IN - India 21
RU - Federazione Russa 20
PL - Polonia 14
SG - Singapore 12
CA - Canada 11
KG - Kirghizistan 11
BE - Belgio 7
HK - Hong Kong 7
ES - Italia 6
EU - Europa 6
JP - Giappone 6
MY - Malesia 6
NL - Olanda 6
UZ - Uzbekistan 6
CL - Cile 5
AU - Australia 4
BR - Brasile 4
GR - Grecia 4
TR - Turchia 4
BD - Bangladesh 3
CH - Svizzera 3
IL - Israele 3
RO - Romania 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
DK - Danimarca 2
RS - Serbia 2
SI - Slovenia 2
VN - Vietnam 2
EG - Egitto 1
HU - Ungheria 1
IR - Iran 1
KZ - Kazakistan 1
MD - Moldavia 1
MN - Mongolia 1
NO - Norvegia 1
TH - Thailandia 1
Totale 14.445
Salva come PNG Salva come JPEG
Città #
Wilmington 3.391
Houston 3.235
Woodbridge 2.210
Fairfield 911
Chandler 548
Ashburn 501
Seattle 401
Cambridge 318
Ann Arbor 305
Dublin 288
Medford 214
Beijing 121
Lawrence 103
Dearborn 102
Jacksonville 80
San Diego 65
New York 49
Rome 40
Zhengzhou 29
Redwood City 25
London 22
Seoul 19
Menlo Park 18
Shanghai 17
Falls Church 14
Kraków 14
Esslingen am Neckar 13
Milan 13
Pune 13
Norwalk 12
Mountain View 10
Saint Petersburg 9
Hefei 8
Perugia 8
Brussels 7
Hong Kong 7
Mülheim 7
Boardman 6
Detroit 6
Guangzhou 6
Nanchang 6
Nanjing 6
Ottawa 6
Palo Alto 6
San Mateo 6
Frosinone 5
Kilburn 5
Putrajaya 5
Engelhard 4
Renton 4
Washington 4
Casarile 3
Chengdu 3
Coushatta 3
Hebei 3
Helsinki 3
Hyderabad 3
Islington 3
Jinan 3
Lausanne 3
Los Angeles 3
Madrid 3
Rapallo 3
San Giorgio di Nogaro 3
São Paulo 3
Toronto 3
Wandsworth 3
Wuhan 3
Ōtsu 3
Augusta 2
Berlin 2
Bologna 2
Chions 2
Chiswick 2
Clearwater 2
Del Norte 2
Dhaka 2
Dong Ket 2
Giugliano In Campania 2
Jinhua 2
Kunming 2
Melbourne 2
Monte Vista 2
Pescara 2
Phoenix 2
Piombino Dese 2
San Francisco 2
Shenyang 2
Southwark 2
Sundern 2
Taranto 2
Verona 2
Acton 1
Albano Laziale 1
Albino 1
Amsterdam 1
Ankara 1
Antalya 1
Apeldoorn 1
Astana 1
Totale 13.330
Salva come PNG Salva come JPEG
Nome #
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. 431
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 418
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 388
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 383
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 382
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 375
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 374
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 370
Tildrakizumab for treating psoriasis 365
Brodalumab for the treatment of psoriasis 360
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 360
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 353
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 353
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 344
Tofacitinib for the treatment of psoriasis 343
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 341
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 338
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 325
A safety evaluation of guselkumab for the treatment of psoriasis 303
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 289
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 281
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 267
Photo-recall cutaneous reaction to gemcitabine 264
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 264
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 263
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 260
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 245
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 236
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 234
Pharmacotherapeutic management of psoriasis in adolescents and children 220
Successful treatment of psoriatic crumbly nails with ustekinumab 207
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 199
Skin immunity and its dysregulation in psoriasis 199
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 191
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 185
Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life 174
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 157
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 154
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 144
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 138
Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study 136
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab 129
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 124
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers 120
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 114
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience 111
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 110
Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension 101
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 98
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 94
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 93
Effect of secukinumab on perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study 81
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 76
Genetic markers predictive of clinical response to biological drugs in psoriasis. 74
Efalizumab 70
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 65
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 64
Italian guidelines in diagnosis and treatment of alopecia areata 64
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 62
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 62
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 61
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 60
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 59
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 59
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 55
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis 55
Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study 55
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 54
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 53
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 52
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 48
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 48
Long-term efficacy of adalimumab in generalized pustular psoriasis 47
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 42
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry 42
Linear psoriasis following the typical distribution of the sciatic nerve 40
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 40
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 40
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 39
Clinical severity instruments 39
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients 38
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 38
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 36
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 36
Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis 35
Italian Guidelines in Pemphigus - adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV) 35
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis 34
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes Abstracts of the 4th Congress of the Psoriasis International Network. July 4-6, 2013. Paris, France 33
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 29
Pruritus characteristics in a large Italian cohort of psoriatic patients 29
Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom 27
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 27
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 27
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 26
Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics 25
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 25
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry 25
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 25
Genetic variations in IL6 and IL12B as protective markers for psoriasis 23
Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study 23
Totale 14.909
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.517
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.517
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.000 0 0 0 0 0 0 0 0 0 259 344 397
2019/20204.475 283 273 243 376 393 459 380 384 502 546 336 300
2020/20213.639 331 347 325 385 418 551 469 345 120 170 126 52
2021/20221.173 65 108 107 35 29 52 148 44 93 88 85 319
2022/20231.285 147 138 116 123 83 310 94 64 109 21 48 32
2023/2024433 44 14 23 13 68 122 70 67 5 7 0 0
Totale 15.060